Triple repeat diseases of the nervous system

Sample

Sverre Heim, Felix Mitelman

Over the past decade, cancer cytogenetics has become widely recognized both as a basic research tool for investigations of tumor biology and a clinical methodology providing vital insights into cancer development and progression. Written by two leading experts, Cancer Cytogenetics, Second Edition provides an authoritative description of neoplastic processes at the chromosomal level of genomic organization. The book opens with a summary of cytogenetic methods and terminology, then reviews the key aspects of chromosomal abnormalities in cancer. The remainder of the book is devoted to the karyotypic and molecular genetic characteristics of specific neoplastic disorders and their clinical implications. Included in these sections are eleven entirely new chapters focusing on different types of non-hematologic neoplasms. This extensive expansion from the single-chapter coverage of the first edition was necessitated by a veritable explosion of knowledge in the field of solid tumor cytogenetics. . Specific topics in the Second Edition include: acute and chronic myeloproliferative disorders; myelodysplastic syndromes; acute and chronic lymphoproliferative disorders; malignant lymphomas; and solid tumors of the respiratory, digestive, and urinary tracts; breast, genital, endocrine, and nervous systems; eye, skin, and bone; and soft tissue. This Second Edition of Cancer Cytogenetics is a valuable resource for researchers in a wide range of fields, including cytogenetics, medical and molecular genetics, cellular and molecular biology, oncology, and hematology. With its complete coverage of the cytogenetic mechanisms underlying neoplasia, this text will also be an indispensable reference for all clinicians involved in the diagnosis and treatment of cancer patients.

Sample

Francis Galton

Galton founded the science of Eugenics and coined the word in 1883. He investigated the families of great men and thought genius was hereditary.

Sample

Theresa Wizemann and Adam C. Berger, rapporteurs

"Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person's response to certain drugs, estimate the risk of developing Alzheimer's disease, and make other predictions based on known links between genes and diseases. However, genetic tests have yet to become a routine part of medical care, in part because there is not enough evidence to show they help improve patients' health.The Institute of Medicine (IOM) held a workshop to explore how researchers can gather better evidence more efficiently on the clinical utility of genetic tests. Generating Evidence for Genomic Diagnostic Test Development compares the evidence that is required for decisions regarding clearance, use, and reimbursement, to the evidence that is currently generated. The report also addresses innovative and efficient ways to generate high-quality evidence, as well as barriers to generating this evidence. Generating Evidence for Genomic Diagnostic Test Development contains information that will be of great value to regulators and policymakers, payers, health-care providers, researchers, funders, and evidence-based review groups."--Publisher's description.

Sample

Thomas L. Lemke, David A. Williams

This edition places emphasis on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems.